E Fund Management Co., Ltd. Uni Qure N.V. Transaction History

E Fund Management Co., Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$5.63 - $8.27 $2,184 - $3,208	-388 Reduced 1.93%	19,687 $133,000
Q3 2023 Nov 13, 2023	BUY	$6.71 - $11.83 $63,221 - $111,462	9,422 Added 88.44%	20,075 $135,000
Q2 2023 Aug 11, 2023	SELL	$11.12 - $22.2 $17,714 - $35,364	-1,593 Reduced 13.01%	10,653 $122,000
Q1 2023 May 11, 2023	BUY	$18.7 - $23.07 $35,455 - $43,740	1,896 Added 18.32%	12,246 $247,000
Q4 2022 Feb 14, 2023	SELL	$18.12 - $27.32 $74,654 - $112,558	-4,120 Reduced 28.47%	10,350 $235,000
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $69,719 - $104,867	4,106 Added 39.62%	14,470 $271,000
Q2 2022 Aug 15, 2022	BUY	$13.15 - $20.45 $82,595 - $128,446	6,281 Added 153.83%	10,364 $193,000
Q1 2021 May 12, 2021	BUY	$29.24 - $42.03 $119,386 - $171,608	4,083 New	4,083 $137,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.